GlassScriptPhysician profile
Shelby Hampton
NPI 1710965108
$2,588.65
in general payments reported to CMS, 2019-2025
29 companies · $533 in 2025
The $533 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $186 · 2021: $384 · 2022: $350 · 2023: $497 · 2024: $358 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,375 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,374.78 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $433.35 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $324.20 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $291.61 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $245.05 | 2021-2025 | |
| Millicent US INC | $176.32 | 2023-2025 | Femring, Intrarosa, Femlyv |
| Myovant Sciences INC. | $150.90 | 2021-2022 | |
| Hologic Sales and Service, LLC | $107.32 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Biogen, INC. | $102.58 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $95.23 | 2019-2022 | |
| Pfizer INC. | $78.79 | 2021-2024 | |
| Avion Pharmaceuticals | $71.22 | 2021-2023 | Balcoltra |
| Shield Therapeutics INC | $62.96 | 2023-2025 | Accrufer |
| Astellas Pharma US INC | $61.85 | 2023-2025 | Veozah |
| Scynexis, INC. | $42.09 | 2022 | |
| Exact Sciences Corporation | $37.36 | 2024-2025 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $36.34 | 2021-2023 | Phexxi |
| Duchesnay USA Incorporated | $34.74 | 2019 | |
| Merck Sharp & Dohme LLC | $29.83 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $29.10 | 2023 | Exparel |
| Coopersurgical, INC. | $28.99 | 2023 | Paragard T 380a |
| Sage Therapeutics, LLC | $20.57 | 2022 | |
| Organon LLC | $20.46 | 2021 | |
| Ibsa Pharma INC. | $19.27 | 2024 | Licart, Tirosint |
| Aspira Women'S Health INC | $18.23 | 2020 | |
| Mylan Pharmaceuticals INC. | $15.15 | 2021 | |
| Boston Scientific Corporation | $14.80 | 2024 | Lux-Dx Insertable Cardiac Monitor |
| Amag Pharmaceuticals, INC. | $14.58 | 2019 | |
| Bausch Health US, LLC | $13.14 | 2020 | |
| Agile Therapeutics, INC. | $12.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelby Hampton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.